You are on page 1of 3
 
ffi
fi
(-s+{
Eqa
-4'->' l-
tffi\
lcm?
I
t\rgrl
I
i]."1flt[?? E1,"3[
\67
qrrfu
3Trgftsrr{
sr$iqri
cRrq
wr*a r5sun
F+mr
fiFt
(sr.)qfi{rc
qpfe,
q-aq
*
(,rg1.
g\q. \s.j{rr$fr
@.),
qcsrr6t
t{.).
\s\'frfi,
(sc qc. cslg'(rfl.
qst.{qqfl,
sq\rs6.
qs.vr.r..
a.('(.s.
gfua,
qr{n
((6r{
FrR4
3r3qsrr frqrq
wrea
gs
cR-qR
6flM
4rrfrq
G
qaAkrcn',
s{r$
S
sc
arm
Prof. (Dr,) Balram Bhargava,
padmashri
MO, DM, FRCP
(Ghso.),
FRCP
(Edln.),
FACC.
FAHA
FAI.IS. FNASC, FASC,
FNA,
DSC
Secretary to the Goyernment
ot lndia
D€parlm€nt
ol
H€atih ResearchMinistry
ol
Health
&
Fsmily
wo[are
&
Director€ensral,
ICMR
ersGqRqnoarq
{zroq
rTr{f,
(T6R
ff
<rqfirrerft
r+r.
siqrft
T.n
r{ffi-
rro
ozs
lndian Council
of
Medical Research
Oepartment
of
Health ResearchMinistry
of
Heatth
&
Family WelfareGovemment
of
lndia
V
Ramalingaswami
Bhawan,
Ansari
Nagar
New
Delhi
-
110
029
O.O.No.
EC
D/COVID'l
9/M
isc./2020
2nd
July
,
2o2o
Dear Colleagues (As
per list attached),
Greetings
from
the
lndian
Council
of
Medical
Research (ICMR)
This
is
to
bring
to
your
kind
attention
that
ICMR
has
partnered
with
Bharat Biotech
lnternational
Limited
(BBIL)
to fast-track
clinical
trials of the
indiSenous CoVID-19 vaccine (BBV152
COVID
Vaccine).This
is
the first
indigenous
vaccine
being
developed
by
lndia
and
is
one
of
the
top
Priority
prolects which
is
being
monitored
at the
topmost
level of
the
Government.
The vaccine
is
derived
from
a
strain
of
SARS-
CoV-z
isolated
by
tCMR-National
lnstitute
of
Virology, Pune.
ICMR
and
BBIL
are
jointly
working
for
the
preclinical
as
well
as
clinical
development of this
vaccine.
It
is
envisaged
to
launch
the
vaccine
for
public health
use
latest
by 15thAugust2020
after
completion of
all
clinical
trials.
BBIL is
working expeditiously
to
meet the
target,
however
finaloutcome will
depend
on
the
cooperation of
all clinical
trial
sites
involved
in
this
pro.iect.
you
have been chosen
as
a clinical
trial
site
of the
BBV152 COVID
vaccine. ln view
of the
public
healthemergency due
to
COVID-19
pandemic and
urgency
to
launch
the
vaccine,
you are
strictly
advised
to
fast
track
all
approvals
related
to
initiation
of
the
clinical
trial
and
ensure
that the
subiect enrollment
is
initiated
no
later than
7th
July 2020.Kindly
note
that
non-compliance
will
be
viewed very
seriously. Therefore, you are
advised
to treat
this
project
on highest
priority
and
meet the
given
timelines
without
any
lapse.
With
regardsYours sincerely
er//44L
D&eryr-
(Balram
Bhargava)
Copy
to:
1.Dr. Krishna
Ella,
CMD, Bhart Biotech, Hyderabad,
AP
2.0r.
Krishna
Mohan,
Sr.Vice-President, Bharat Biotech, Hyderabad,
AP
Tele.: 26588204, 26589620, Fax
(Off.):91-'l
l-26588662'
E-mail:
secy{g@icmr.gov
in
 
-
o
\o
(
ga
t1
IP
avFot 7o
6
o;:
5
oi o- *.
oo-
oa
o
o
o-
q=
l
r x-7
rlo
s.=a-=2-
=-
;'d
nio=ar.)
D)
, I=
-rax
kro Y.
-'
lPgo
lo
I
ZF<
:?r -=P-I
o)
ai
e =9
q)
<'==-
aD
O-1^oe -)p
o
<
^i-
l0
I
FZ9TI
3
<3
r"l
@'-
-;
I
s^
=.o
='
tdo
2.>oo
{
=B
P
OqAS
(D'id
=>'e
_:
a'a
(
ts"f
;
T
II
I
III
FC:9UU=z
lDdt>
x-= L/
o
,9A -o ro
i'')
I= /J
=y
=
=c)
E)
a7 =
AF
^
<
I
>x-lol
J@
ra
)l
: ^c -l
iBEiI
*qt
*Fl
2-]I,
J
Z
t:-
l<
lo)t=l eI
'Et
lF)
z
o
=AE
:t(D
l(
r^\
t-
t?
t..t=
l3
E'
lo-
l:.
la
liili.
t:-
l.)
l='
lq l-
ls)
t
i'
1>
la)
l5
lo
lo
tE
la
to-
(o
E
lr-
lo0:
=
lc
1
{r,l
Itz
l;
=
lo
3
lo-
h
l=
l=
br
a
{a
0'.
l=
lo
l3
la-
lolo
l:1
lrD
t=:
la)
lb
k
lo-
L='
ll1i
la
6
le.
li
lo-
lc
o-
l='
1..
E
lrr
t=
,II,,
lE
t:.l-
a
IJ
to
tx'
l=
0c
hr
l(D
la-(F)
Ua
t3
le.
t-
li)
EI
>o
Aa
rEa
f-N O O r
E
z=
EP
.=<0n
:-r-a+
.i e F€
S
=-=A) (,
}Q ?
6
z
= O+=oa
o;
?
^=.
:i
. =
o--
o-
a
3
I
o
:OF'Etr
6'6
7e.>
tr ='+ ='i
= @ == a
'-
aA'
C'
v
- li -Et ^a
E
39Y9S
f?.cpzE
'i'rE
J'
H>"-t
q9
q-
E
z d "i
-' -
6-
:-z
AJE6-
 >z-
T=AA:7 R
o
=.$ -z
{
a
E',n
f.a6='''E =0a^S=IDQ -
P3
9.
o
z>=o
t
<
ar
Oa2,J
=>.dz
.d 47
=B.oE
N=l r
\o
dE
J
rD
='
l='l6
FC U3U
oJ: (DA:r
T? oE
X" ra
 r ( :-- i;
B)
7:1 \)= 0
<
.2U)g-F,
--i f o
(
( P / =
*xd i
a
<'*
9.4
9
=^;
oU
>AUtr
==.D:r
+oa E x
- ^1'
o8
i i
Qrd =-
'o o
R
.3
5
;.{
9a>
=.d
a
<z\I
E
3,r
I
4;'E
I
A,=A
I Bli
y
l3c
T
z
 
;
l 0
llo.
E
(e)
Ua
l=
t
ti*
L;
lo-
lo
lq
It
IC'ha
l='
t-
l*J
L-r
(s)
q9
lo)
lb
lo
lo
to-
lo
l:r
l=
la)
IL
l-_
{o
E
lF)
l=
lo-
tf
l=
0a
{R)
l. .
1l
ls
t=
l D
lbb.
ta
la')
k
ts
l J
li
Itr
l5
IT
lo)
to
h._
l=
t?.t-lh
lo
lrD
lo-
ls
l--
q1
to
Ur
lP.
t-
A
lol3
=
 
al
vl
z1
zt
6'
a
o
s
6-
0a
:E
o
 .
et
F
aaF
-)Oao
I ?2
: _ai
EZa
ES
o
-/\=
.p
d
i"
^.,
=
2:
?i;
'
t-)
ao o
a-
-*.
ci >
PL<B
a-r\
<l
o
ooi
ii99
t-.i
H.E
.Y
c,a7
; =\,
c
(D
== 6
TE
xE'
-:iD=
 
=oa
0) iii
=_
'z1
0a
D
ro
a\o
3aT9
.D
\of =
9>H
+
\< I=
poP
*P.L'
fi
s_9
= -9'on
t
c)<zioO(,
o =r=o O:r
r"
Ei g;
(,
(IO FJ C
O)
(n
E -,
=0a
O:5B
E
3\-)' 6 ') O --'\u,:i
- .j 'i- .
,j,
-
g{ :
K
rc)+<
iS
o-
'- ;rf(J
a+
'-
D)
lto
l6-
t-.te
lo
to
(_o
lhlo-
tc
t.-.
to-
l3
l=
t,;lolx
l:.
l:-
lO-
l.,
l:r
lc
l=-
It
lDi
R
tr3,
tal3
to-
la
fio
llo
l2
t;
lo-
["=)
0c
t3lP.
l-
t3
7,FAA
b)
'
iE
(i
AE<E
c =an I
P- () =.4
=
i 99
ia o;
I a=c)
g
,EI
3
cs
<%
B
nZ+oPc,;-iu: a
oq
its
6'
t+
==.>
 +
tlJ
oE
>
'n
:1
x
<=>
2>V
i ;mo=vEryoo
ga
R'2
qs'
r'a
IDEUP-'-.
o9.P
gqc
P
3
'ojrUI
tu
0a
x
7
,E
.tr'
C/'
Pa=
a
V-
na=
< _2.L5
P
i-=
9Fd'Y
Bi97o
oal
dJ E t,
F)
X -, =oq
I:68
E
p o --1
^-= t -
=
q9. A'-
a= 6i
36
:'+
o(J
e:-
6
oa
5
m
btl
{s)
UaL=
l6
l=
lo
l3
l<l=
l-
llD
ts
lo
{o
lo
IP
l o
t-.
r=
lo-
ij-.
lE
t)
t<
la
6
E
IJ
l=
lo
lo-
lk
oi
l2
l.i
o_
l6-{a)
tr
3
11.
t-lo
l=

Reward Your Curiosity

Everything you want to read.
Anytime. Anywhere. Any device.
No Commitment. Cancel anytime.
576648e32a3d8b82ca71961b7a986505